Tarek A Hammad

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Suicide rates in short-term randomized controlled trials of newer antidepressants
    Tarek A Hammad
    Division of Neuropharmocological Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993 0002, USA
    J Clin Psychopharmacol 26:203-7. 2006
  2. ncbi Suicidality in pediatric patients treated with antidepressant drugs
    Tarek A Hammad
    Division of Neuropharmacological Drug Products, HFD 120, 5600 Fishers Lane, Rockville, MD 20857, USA
    Arch Gen Psychiatry 63:332-9. 2006
  3. ncbi Atomoxetine use during a period of FDA actions
    Dongyi Tony Du
    Office of Commissioner, US Food and Drug Administration FDA, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
    Med Care 50:987-92. 2012
  4. ncbi Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration
    Marc Stone
    Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993 0002, USA
    BMJ 339:b2880. 2009
  5. ncbi Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008
    Ann W McMahon
    Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA
    Pharmacoepidemiol Drug Saf 19:921-33. 2010
  6. ncbi Predicting nosocomial bloodstream infections using surrogate markers of injury severity: clinical and methodological perspectives
    Maher M El-Masri
    University of Windsor, Faculty of Nursing, Windsor, Ontario, Canada
    Nurs Res 54:273-9. 2005

Collaborators

Detail Information

Publications6

  1. ncbi Suicide rates in short-term randomized controlled trials of newer antidepressants
    Tarek A Hammad
    Division of Neuropharmocological Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993 0002, USA
    J Clin Psychopharmacol 26:203-7. 2006
    ....
  2. ncbi Suicidality in pediatric patients treated with antidepressant drugs
    Tarek A Hammad
    Division of Neuropharmacological Drug Products, HFD 120, 5600 Fishers Lane, Rockville, MD 20857, USA
    Arch Gen Psychiatry 63:332-9. 2006
    ..There has been concern that widely used antidepressant agents might be associated with an increased risk of suicidal ideation and behavior (suicidality) in pediatric patients...
  3. ncbi Atomoxetine use during a period of FDA actions
    Dongyi Tony Du
    Office of Commissioner, US Food and Drug Administration FDA, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
    Med Care 50:987-92. 2012
    ..At FDA's request, the manufacturer subsequently added a boxed warning to the drug's labeling on November 8, 2005...
  4. ncbi Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration
    Marc Stone
    Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993 0002, USA
    BMJ 339:b2880. 2009
    ..To examine the risk of suicidal behaviour within clinical trials of antidepressants in adults...
  5. ncbi Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008
    Ann W McMahon
    Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA
    Pharmacoepidemiol Drug Saf 19:921-33. 2010
    ..The investigation identified Baxter Healthcare-brand heparin product due to its strongest association with the events. Later, oversulfated chondroitin sulfate (OSCS), a heparin-like contaminant, was discovered...
  6. ncbi Predicting nosocomial bloodstream infections using surrogate markers of injury severity: clinical and methodological perspectives
    Maher M El-Masri
    University of Windsor, Faculty of Nursing, Windsor, Ontario, Canada
    Nurs Res 54:273-9. 2005
    ..However, surrogate markers of injury severity (SMIS) may be more clinically meaningful than these commonly used numerical injury severity indices with respect to the control and prevention of nosocomial BSI...